About astrazeneca plc - AZN
AZN At a Glance
| Phone | 44-20-3749-5000 | Revenue | 54.10B | |
| Industry | Pharmaceuticals: Major | Net Income | 7.04B | |
| Sector | Health Technology | 2024 Sales Growth | 17.629% | |
| Fiscal Year-end | 12 / 2025 | Employees | 94,300 | |
| View SEC Filings |
AZN Valuation
| P/E Current | 29.233 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 28.86 |
| Price to Sales Ratio | 3.786 |
| Price to Book Ratio | 4.982 |
| Price to Cash Flow Ratio | 16.776 |
| Enterprise Value to EBITDA | 12.851 |
| Enterprise Value to Sales | 4.243 |
| Total Debt to Enterprise Value | 0.132 |
AZN Efficiency
| Revenue/Employee | 573,655.921 |
| Income Per Employee | 74,633.725 |
| Receivables Turnover | 4.131 |
| Total Asset Turnover | 0.527 |
AZN Liquidity
| Current Ratio | 0.927 |
| Quick Ratio | 0.737 |
| Cash Ratio | 0.203 |
AZN Profitability
| Gross Margin | 74.982 |
| Operating Margin | 23.651 |
| Pretax Margin | 16.124 |
| Net Margin | 13.01 |
| Return on Assets | 6.861 |
| Return on Equity | 17.611 |
| Return on Total Capital | 9.901 |
| Return on Invested Capital | 10.764 |
AZN Capital Structure
| Total Debt to Total Equity | 74.278 |
| Total Debt to Total Capital | 42.62 |
| Total Debt to Total Assets | 29.12 |
| Long-Term Debt to Equity | 67.717 |
| Long-Term Debt to Total Capital | 38.856 |
Astrazeneca Plc in the News
Sanofi takes another big hit as it halts work on breast cancer medication, amcenestrant
French healthcare company Sanofi has decided to halt work on its once praised breast cancer medication amcenestrant after a second failed clinical trial.
AstraZeneca sees $4B in COVID-19 vaccine sales
AstraZeneca recorded a big jump in revenue on Thursday as it begins to take a profit from its coronavirus vaccine for the first time.
Some vaccines last a lifetime. Here’s why COVID-19 shots don’t.
Why don’t COVID-19 vaccinations last longer?
Merck COVID-19 pill success slams Moderna shares, shakes up health care sector
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
COVID-19 vaccine boosters could mean billions for drugmakers
Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans' protection against the virus.
FDA resignations over White House booster shot guidance a 'mess for administration'
Reports that Food and Drug Administration officials plan to step down over the White House’s COVID-19 booster shot guidance have created a “mess” for the Biden administration, according to Dr. Mark Siegel.
Biden pushes Congress to allow Medicare to negotiate drug prices
President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected to push Congress to pass legislation that would allow Medicare to negotiate drug prices for millions of Americans.
J&J COVID-19 vaccine shows promising early signs of protecting against Delta variant
The new findings “reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.
FDA, J&J near deal for COVID-19 vaccine production at Baltimore plant
The Food and Drug Administration and vaccine maker Johnson & Johnson expect to announce as early as Friday that contamination problems at a COVID-19 vaccine plant in Baltimore are resolved, clearing the way for millions more doses to become available.
Bill Gates and US Trade rep talk vaccines
Microsoft co-founder Bill Gates and United States Trade Representative Katherine Tai held a virtual meeting on Tuesday to discuss increasing COVID-19 vaccine production, global health issues and the proposed waiver to certain provisions of the World Trade Organization’s (WTO) agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) related to the pandemic.